

U.S.S.N. 09/360,242
MCDONALD *et al.*
AMENDMENT

95. (New) The method of claim 35, wherein the immune effector cells are selected from among monocytes, macrophages, leukocytes and microglia.

Please replace claims 29, 35 and 89 with amended claims 29, 35 and 89 follows:

29. (Thrice Amended) A method for treating pathological conditions by treating the underlying pathology associated with inflammatory responses and secondary tissue damage associated with activation, proliferation and migration of immune effector cells by inhibiting activation, proliferation or migration of immune effector cells, comprising administering a conjugate to an animal whereby activation, proliferation, migration of the immune effector cells is inhibited wherein:

the conjugate comprises a targeted agent or a portion thereof and a chemokine receptor targeting agent or a portion thereof sufficient to bind to a chemokine receptor on immune effector cells and facilitate internalization of the conjugate;

the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the chemokine, antibody or fragment thereof binds to the receptor and internalizes the targeted agent in a cell;

the targeted agent or portion thereof, when internalized in a cell, alters metabolism or gene expression in the cell, regulates or alters protein synthesis in the cell, inhibits proliferation of the cell or kills the cell; and

the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

35. (Twice Amended) A method of targeted delivery of an agent into cells that express chemokine receptors, comprising associating the agent with a chemokine receptor targeting agent, whereby:

the chemokine receptor targeting agent binds to a chemokine receptor expressed on the cells; and